TAP2 and head and neck squamous cell carcinoma: Similarly, Chikamatsu et al. did not identify differences in HLA class I and TAP expression in CSCs vs non-CSCs in head and neck squamous cell carcinoma (HNSCC), although CSCs displayed reduced levels of TAP2.